Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > BUSINESS
BUSINESS
- Astellas, Anokion Join Hands on Immune Tolerance Therapeutics
June 3, 2015
- Merck Serono Names CFO Koji Okamoto as New President
June 2, 2015
- Former Merck Serono President Feliciano Becomes AbbVie G.K.’s New President
June 2, 2015
- Pfizer, Merck Serono Initiate Copromotion for Xalkori
June 2, 2015
- 14-Day Prescription Limit Lifted for Efient: Daiichi Sankyo
June 2, 2015
- Lenvima Receives European Approval: Eisai
June 2, 2015
- Meiji Seika Pharma Seeks Japan Approval for Asenapine
May 29, 2015
- Otsuka Wins EU Approval for ADPKD Drug Jinarc
May 29, 2015
- Eisai Files Ultra-High Dose Mecobalamin for ALS in Japan
May 29, 2015
- Takeda Launches Once-Weekly DPP-4 Inhibitor Zafatek
May 29, 2015
- Sanofi Files NDA for Antiepileptic Treatment Vigabatrin
May 29, 2015
- Astellas Confident about Achieving FY2017 Japan Sales Target
May 28, 2015
- Asahi Kasei’s New Midterm Plan Aims to Maintain Profitability and Expand Sales in Healthcare Field
May 28, 2015
- Fycompa Receives Positive Opinion from CHMP for Adjunct Therapy for PGTC Seizures: Eisai
May 28, 2015
- Sanofi Oncology Business Unit Head Pascal Rigaudy to Become New President of Genzyme Japan
May 28, 2015
- Astellas’s New 3-Year Plan Targets Sales Growth in Mid-Single-Digit Range
May 27, 2015
- GSK’s Aldreb Debuts as Last Resort for Multidrug Resistant Pseudomonas Aeruginosa Infection
May 26, 2015
- Masanobu Suzuki Tapped as President of Nippon Kayaku
May 26, 2015
- Chugai Files NDA for Combination Psoriasis Vulgaris Drug
May 26, 2015
- Celgene Launches Multiple Myeloma Treatment Pomalyst; Keio Professor Acknowledges Its Efficacy in PFS, OS Improvement
May 26, 2015
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…